Table 3 Visual acuity and central subfield thickness (CSMT) during the follow-up.

From: Predictive factors of selective mineralocorticoid receptor antagonist treatment in chronic central serous chorioretinopathy

 

Baseline

Month 3

Month 6

Month 12

Whole cohort

Visual acuity (ETDRS letter)

72.63 ± 12.22

75.03 ± 12.83

75.53 ± 13.05

72.10 ± 16.44

CSMT (µm)

359.13 ± 89.24

303.50 ± 63.96

274.37 ± 47.67

268.50 ± 64.57*

Good responders

Visual acuity (ETDRS letter)

76.00 ± 14.04

78.93 ± 13.39

79.73 ± 13.62

81.00 ± 10.72*

CSMT (µm)

362.60 ± 71.60

302.00 ± 60.85

267.33 ± 39.11

238.67 ± 44.44*

Poor responders

Visual acuity (ETDRS letter)

69.27 ± 9.39

71.13 ± 11.36

71.33 ± 11.37

63.20 ± 16.58†

CSMT (µm)

355.67 ± 106.51

305.00 ± 69.06

281.40 ± 55.41

298.33 ± 68.87†

  1. *p < 0.01 compared to baseline using repeated measures analysis of variance test.
  2. †p < 0.01 compared to good responders using the independent samples student’s t-test.
Back to article page